Bora Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St

March 11, 2025

Bora Pharmaceuticals (TWSE:6472) Full Year 2024 Results

Key Financial Results

Revenue: NT$19.2b (up 36% from FY 2023).
Net income: NT$3.94b (up 30% from FY 2023).
Profit margin: 21% (in line with FY 2023).
EPS: NT$38.69 (up from NT$30.20 in FY 2023).

earnings-and-revenue-growth — TWSE:6472 Earnings and Revenue Growth March 11th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bora Pharmaceuticals EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.3%.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 47% growth forecast for the Pharmaceuticals industry in Taiwan.

Performance of the Taiwanese Pharmaceuticals industry.

The company's shares are down 13% from a week ago.

Valuation

Our analysis of Bora Pharmaceuticals based on 6 different valuation metrics shows it might be undervalued. Click here to find out what a fair price for the stock might be and where analysts see the share price heading over the next year.

Mobile Infrastructure for Defense and Disaster

The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.

Get the investor briefing before the next round of contracts

Valuation is complex, but we're here to simplify it.

Discover if Bora Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.